|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.57 USD | +1.15% |
|
+1.26% | -16.70% |
| 02-27 | Aardvark pauses late-stage trial testing rare disease treatment | RE |
| 02-26 | Soleno Therapeutics Names New Chief Financial Officer | MT |
| Capitalization | 1.97B 1.7B 1.54B 1.47B 2.69B 181B 2.81B 18.15B 7.24B 86.66B 7.39B 7.23B 310B | P/E ratio 2026 * |
9.56x | P/E ratio 2027 * | 5.54x |
|---|---|---|---|---|---|
| Enterprise value | 1.53B 1.32B 1.2B 1.15B 2.09B 140B 2.18B 14.12B 5.63B 67.41B 5.74B 5.62B 241B | EV / Sales 2026 * |
3.27x | EV / Sales 2027 * | 1.6x |
| Free-Float |
92.85% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Soleno Therapeutics, Inc.
| 1 day | +1.15% | ||
| 1 week | +1.26% | ||
| Current month | -1.28% | ||
| 1 month | -2.55% | ||
| 3 months | -24.92% | ||
| 6 months | -44.72% | ||
| Current year | -16.70% |
| 1 week | 36.55 |  | 41.86 |
| 1 month | 32.63 | | 41.86 |
| Current year | 32.63 | | 50.88 |
| 1 year | 32.63 | | 90.32 |
| 3 years | 1.94 | | 90.32 |
| 5 years | 0.85 | | 90.32 |
| 10 years | 0.85 | | 131.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Anish Bhatnagar
CEO | Chief Executive Officer | 58 | 31/12/2016 |
James Mackaness
DFI | Director of Finance/CFO | 62 | 13/11/2019 |
Michael Huang
CTO | Chief Tech/Sci/R&D Officer | - | 31/10/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Anish Bhatnagar
CHM | Chairman | 58 | 31/03/2025 |
Andrew Sinclair
BRD | Director/Board Member | 54 | 20/12/2018 |
Birgitte Volck
BRD | Director/Board Member | 63 | 09/06/2019 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.15% | +1.26% | -14.27% | +1,562.50% | 1.97B | |
| -2.55% | -11.86% | +5.85% | +92.32% | 45.72B | |
| +0.47% | -7.41% | +53.11% | +11.05% | 39.82B | |
| -4.21% | -4.29% | +85.13% | +596.94% | 32.31B | |
| -1.78% | -6.30% | -11.17% | -22.04% | 26.05B | |
| +0.40% | -14.31% | +56.81% | -38.63% | 18.68B | |
| -1.03% | -3.16% | +8.10% | -30.72% | 17.17B | |
| +7.03% | -3.23% | +40.11% | +132.61% | 11.23B | |
| -2.86% | -5.44% | -23.58% | +870.13% | 11.93B | |
| -0.98% | -6.78% | +6.80% | +140.70% | 10.83B | |
| Average | -0.44% | -6.20% | +20.69% | +331.49% | 21.57B | |
| Weighted average by Cap. | -1.18% | -6.06% | +29.01% | +178.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 468M 403M 365M 350M 640M 42.92B 667M 4.32B 1.72B 20.6B 1.76B 1.72B 73.72B | 741M 638M 578M 555M 1.01B 67.94B 1.06B 6.83B 2.72B 32.6B 2.78B 2.72B 117B |
| Net income | 212M 183M 166M 159M 290M 19.47B 303M 1.96B 781M 9.34B 796M 779M 33.44B | 386M 332M 301M 289M 527M 35.4B 550M 3.56B 1.42B 16.99B 1.45B 1.42B 60.8B |
| Net Debt | -437M -377M -341M -328M -598M -40.12B -624M -4.03B -1.61B -19.25B -1.64B -1.61B -68.9B | -785M -676M -613M -588M -1.07B -71.98B -1.12B -7.24B -2.89B -34.54B -2.94B -2.88B -124B |
Employees
182
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/03/26 | 38.57 $ | +1.15% | 1,690,575 |
| 04/03/26 | 38.13 $ | +1.09% | 1,116,610 |
| 03/03/26 | 37.72 $ | -3.43% | 1,472,235 |
| 02/03/26 | 39.06 $ | -0.03% | 1,884,665 |
| 27/02/26 | 39.07 $ | +2.57% | 1,538,774 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
38.13USD
Average target price
107.38USD
Spread / Average Target
+181.63%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SLNO Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition